

Product Data Sheet

[DPro5] Corticotropin Releasing Factor, human, rat TFA

| Cat. No.: | HY-P3684A | | |
|----------------------|--|--|--|
| Molecular Formula: | $C_{208}H_{344}N_{60}O_{63}S_2.xC_2HF_3O_2$ | | |
| Sequence: | Ser-Glu-Glu-Pro-{d-Pro}-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-Glu-U u-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-Met-Glu-Ile-Il e-NH2 | | |
| Sequence Shortening: | SEEP-{d-Pro}-ISLDLTFHLLREVLEMARAEQLAQQAHSNRKLMEII-NH2 | | |
| Target: | CRFR | | |
| Pathway: | GPCR/G Protein | | |
| Storage: | Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) | | |

SOLVENT & SOLUBILITY

In Vitro

H₂O : 50 mg/mL (Need ultrasonic)

| BIOLOGICAL ACTIVITY | | | |
|---------------------|--|---|--|
| Description | [DPro5] Corticotropin Releasing Factor, human, rat TFA is a selective corticotropin releasing factor/hormone R2 (CRH-R2) agonist. [DPro5] Corticotropin Releasing Factor, human, rat TFA fails to cause the typical anxiogenic effect, but modulates learning and memory processes in rat ^[1] . | | |
| In Vitro | [DPro5] Corticotropin Releasing Factor, human, rat TFA (1 nM; 1 h) diminishes the amplitude of hippocampal population spike and prevents the onset of long-term potentiation (LTP) ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | |
| In Vivo | [DPro5] Corticotropin Releasing Factor, human, rat TFA (0.01-1 μg; i.c.v.; single dose) doesn't induce the typical anxiogenic effect, but produces a nonspecific suppression of behavior in Sprague-Dowley rats. And [DPro5] Corticotropin Releasing Factor, human, rat TFA also enhances the short-term memory to a maximum degree and prevented the memory loss induced by diazepam ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | | |
| | Animal Model: | Sprague-Dowley rats ^[1] | |
| | Dosage: | 0.01-1 μg | |
| | Administration: | Intracerebroventricular injection; single dose | |
| | Result: | Decreased the number of visits into the light box in the dark-light test. | |

REFERENCES

[1]. Shabanov PD, et al. [Anxiogenic and mnestic effects of corticoliberin and its analogs introduced into the brain ventriculi of rats]. Eksp Klin Farmakol. 2006 Nov-Dec;69(6):3-8. Russian.

[2]. Rebaudo R, et al. Electrophysiological effects of sustained delivery of CRF and its receptor agonists in hippocampal slices. Brain Res. 2001 Dec 13;922(1):112-7.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA